{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T21:24:03Z","timestamp":1785619443991,"version":"3.56.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:00:00Z","timestamp":1760745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:00:00Z","timestamp":1760745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background &amp; Aims<\/jats:title>\n                    <jats:p>Non-selective beta-blockers (NSBBs) have become a cornerstone treatment to prevent complications of cirrhosis and portal hypertension. Data supporting the use of a specific beta-blocker are scarce. In this retrospective study, we aimed to compare the effectiveness of carvedilol versus propranolol in: 1) preventing recurrent esophageal hemorrhage (EVH) in patients with prior history of EVH 2) reducing the occurrence of further decompensation episodes in these patients including hepatic encephalopathy (HE), ascites, spontaneous bacterial peritonitis (SBP), hepatorenal syndrome (HRS), and hepatocellular carcinoma (HCC), and 3) reducing all-cause mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Approach &amp; Results<\/jats:title>\n                    <jats:p>\n                      This was a retrospective propensity-matched study using the multi-institutional database TriNetX. We included patients with cirrhosis who had an episode of EVH and were prescribed carvedilol or propranolol between December 2004 and December 2024. The primary outcome was the rate of hospitalization with recurrent EVH within the first 5\u00a0years of starting the index NSBB. The secondary outcomes were hospitalization with the principal diagnoses of ascites, SBP, HE, HRS, new diagnosis of HCC, undergoing liver transplant (LT), and all-cause mortality within the observation period of 5\u00a0years of NSBB prescription. Kaplan\u2013Meier survival analysis was also performed. Compared to propranolol use, carvedilol use was associated with lower risk of EVH (RR, 0.898,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), ascites (RR, 0.757,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), SBP (RR, 0.680,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), HRS (RR, 0.734,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), HCC (RR, 0.701,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), undergoing LT (RR, 0.825,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.028) and mortality (RR, 0.640,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). No difference in HE rates (RR, 0.899,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.071) was found between the two groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Compared to propranolol, the use of carvedilol in patients with history of cirrhosis and EVH was associated with lower risk of recurrent EVH, further decompensation episodes, undergoing LT, and mortality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10620-025-09453-6","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T06:18:09Z","timestamp":1760768289000},"page":"1556-1568","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparative Risk of Recurrent Esophageal Variceal Hemorrhage and Other Decompensation Events with Carvedilol Versus Propranolol in Patients with Cirrhosis: A Retrospective Study"],"prefix":"10.1007","volume":"71","author":[{"given":"Abdellatif","family":"Ismail","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Abusuliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Kloub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahem","family":"Abbarh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Aloum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa Suhail","family":"Najim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Al-Aquily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud Y.","family":"Madi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing-Kin","family":"Syn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,18]]},"reference":[{"key":"9453_CR1","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/S0140-6736(21)01374-X","volume":"398","author":"P Gin\u00e8s","year":"2021","unstructured":"Gin\u00e8s P, Krag A, Abraldes JG, Sol\u00e0 E, Fabrellas N, Kamath PS. Liver cirrhosis. The Lancet. 2021;398:1359\u20131376. https:\/\/doi.org\/10.1016\/S0140-6736(21)01374-X.","journal-title":"The Lancet."},{"key":"9453_CR2","doi-asserted-by":"publisher","first-page":"179","DOI":"10.5662\/wjm.v13.i4.179","volume":"13","author":"R Kumar","year":"2023","unstructured":"Kumar R, Kumar S, Prakash SS. Compensated liver cirrhosis: Natural course and disease-modifying strategies. World J Methodol. 2023;13:179\u2013193. https:\/\/doi.org\/10.5662\/wjm.v13.i4.179.","journal-title":"World J Methodol."},{"key":"9453_CR3","doi-asserted-by":"publisher","first-page":"s60","DOI":"10.7861\/clinmedicine.18-2-s60","volume":"18","author":"D Mansour","year":"2018","unstructured":"Mansour D, McPherson S. Management of decompensated cirrhosis. Clinical Medicine. 2018;18:s60\u2013s65. https:\/\/doi.org\/10.7861\/clinmedicine.18-2-s60.","journal-title":"Clinical Medicine."},{"key":"9453_CR4","doi-asserted-by":"publisher","first-page":"e0290352","DOI":"10.1371\/journal.pone.0290352","volume":"18","author":"M Schwarz","year":"2023","unstructured":"Schwarz M, Schwarz C, Burghart L et al. Late-stage presentation with decompensated cirrhosis is alarmingly common but successful etiologic therapy allows for favorable clinical outcomes. PLoS ONE. 2023;18:e0290352. https:\/\/doi.org\/10.1371\/journal.pone.0290352.","journal-title":"PLoS ONE."},{"key":"9453_CR5","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jceh.2012.08.001","volume":"2","author":"M Sharma","year":"2012","unstructured":"Sharma M, Rameshbabu CS. Collateral Pathways in Portal Hypertension. J Clin Exp Hepatol. 2012;2:338\u2013352. https:\/\/doi.org\/10.1016\/j.jceh.2012.08.001.","journal-title":"J Clin Exp Hepatol."},{"key":"9453_CR6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cld.2013.12.001","volume":"18","author":"Y Iwakiri","year":"2014","unstructured":"Iwakiri Y. Pathophysiology of Portal Hypertension. Clinics in Liver Disease. 2014;18:281\u2013291. https:\/\/doi.org\/10.1016\/j.cld.2013.12.001.","journal-title":"Clinics in Liver Disease."},{"key":"9453_CR7","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S0140-6736(80)90063-X","volume":"316","author":"D Lebrec","year":"1980","unstructured":"Lebrec D, Corbic M, Nouel O, Benhamou JP. PROPRANOLOL\u2014A MEDICAL TREATMENT FOR PORTAL HYPERTENSION? The Lancet. 1980;316:180\u2013182. https:\/\/doi.org\/10.1016\/S0140-6736(80)90063-X.","journal-title":"The Lancet."},{"key":"9453_CR8","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1056\/NEJMra1504367","volume":"375","author":"PS Ge","year":"2016","unstructured":"Ge PS, Runyon BA. Treatment of Patients with Cirrhosis. Campion EW, ed. N Engl J Med. 2016;375:767\u2013777. https:\/\/doi.org\/10.1056\/NEJMra1504367.","journal-title":"N Engl J Med."},{"key":"9453_CR9","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","volume":"393","author":"C Villanueva","year":"2019","unstructured":"Villanueva C, Albillos A, Genesc\u00e0 J. \u03b2 blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet Lond Engl. 2019;393:1597\u20131608. https:\/\/doi.org\/10.1016\/S0140-6736(18)31875-0.","journal-title":"Lancet Lond Engl."},{"key":"9453_CR10","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jhep.2022.05.021","volume":"77","author":"C Villanueva","year":"2022","unstructured":"Villanueva C, Torres F, Sarin SK et al. Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis. J Hepatol. 2022;77:1014\u20131025. https:\/\/doi.org\/10.1016\/j.jhep.2022.05.021.","journal-title":"J Hepatol."},{"key":"9453_CR11","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/apt.17824","volume":"59","author":"C Villanueva","year":"2024","unstructured":"Villanueva C, Sapena V, Lo GH et al. Improving primary prophylaxis of variceal bleeding by adapting therapy to the clinical stage of cirrhosis. A competing-risk meta-analysis of individual participant data. Aliment Pharmacol Ther. 2024;59:306\u2013321. https:\/\/doi.org\/10.1111\/apt.17824.","journal-title":"Aliment Pharmacol Ther."},{"key":"9453_CR12","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1002\/hep.30220","volume":"69","author":"M Sharma","year":"2019","unstructured":"Sharma M, Singh S, Desai V et al. Comparison of Therapies for Primary Prevention of Esophageal Variceal Bleeding: A Systematic Review and Network Meta-analysis. Hepatology. 2019;69:1657\u20131675. https:\/\/doi.org\/10.1002\/hep.30220.","journal-title":"Hepatology."},{"key":"9453_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2019.12.001","volume":"2","author":"SG Rodrigues","year":"2020","unstructured":"Rodrigues SG, Mendoza YP, Bosch J. Beta-blockers in cirrhosis: Evidence-based indications and limitations. JHEP Reports. 2020;2:100063. https:\/\/doi.org\/10.1016\/j.jhepr.2019.12.001.","journal-title":"JHEP Reports."},{"key":"9453_CR14","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1097\/HEP.0000000000000647","volume":"79","author":"DE Kaplan","year":"2024","unstructured":"Kaplan DE, Ripoll C, Thiele M. AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatol Baltim Md. 2024;79:1180\u20131211. https:\/\/doi.org\/10.1097\/HEP.0000000000000647.","journal-title":"Hepatol Baltim Md."},{"key":"9453_CR15","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","volume":"76","author":"R De Franchis","year":"2022","unstructured":"De Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Abraldes JG, Albillos A, Baiges A, Bajaj J, Ba\u00f1ares R, Barrufet M. Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2022;76:959\u2013974. https:\/\/doi.org\/10.1016\/j.jhep.2021.12.022.","journal-title":"J Hepatol."},{"key":"9453_CR16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/hep.510300124","volume":"30","author":"R Ba\u00f1ares","year":"1999","unstructured":"Ba\u00f1ares R, Moitinho E, Piqueras B et al. Carvedilol, a new nonselective beta-blocker with intrinsic anti-alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology. 1999;30:79\u201383. https:\/\/doi.org\/10.1002\/hep.510300124.","journal-title":"Hepatology."},{"key":"9453_CR17","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/apt.12634","volume":"39","author":"E Sinagra","year":"2014","unstructured":"Sinagra E, Perricone G, D\u2019Amico M, Tin\u00e8 F, D\u2019Amico G. Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis. Aliment Pharmacol Ther. 2014;39:557\u2013568. https:\/\/doi.org\/10.1111\/apt.12634.","journal-title":"Aliment Pharmacol Ther."},{"key":"9453_CR18","first-page":"857","volume":"36","author":"Muhammad Farooq Hanif","year":"2023","unstructured":"Hanif Muhammad Farooq, Fiaz Raja Omer, Iqbal Muhammad Adnan et al. Comparison of carvedilol and propranolol for primary prophylaxis of esophageal variceal bleed in cirrhotic patients. Pak J Pharm Sci. 2023;36:857\u2013862.","journal-title":"Pak J Pharm Sci."},{"key":"9453_CR19","doi-asserted-by":"publisher","unstructured":"Zacharias AP, Jeyaraj R, Hobolth L, Bendtsen F, Gluud LL, Morgan MY. Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices. Cochrane Hepato-Biliary Group, ed. Cochrane Database of Systematic Reviews. 2018;2018(10). https:\/\/doi.org\/10.1002\/14651858.CD011510.pub2","DOI":"10.1002\/14651858.CD011510.pub2"},{"key":"9453_CR20","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1016\/j.cgh.2022.06.007","volume":"21","author":"M Jachs","year":"2023","unstructured":"Jachs M, Hartl L, Simbrunner B. Carvedilol Achieves Higher Hemodynamic Response and Lower Rebleeding Rates Than Propranolol in Secondary Prophylaxis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2023;21:2318\u20132326. https:\/\/doi.org\/10.1016\/j.cgh.2022.06.007.","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc."},{"key":"9453_CR21","doi-asserted-by":"publisher","unstructured":"Fortea JI, Alvarado-Tapias E, Simbrunner B. Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis. J Hepatol Published online December. 17, 2024:S0168\u20138278(24)02772\u20137. https:\/\/doi.org\/10.1016\/j.jhep.2024.12.017","DOI":"10.1016\/j.jhep.2024.12.017"},{"key":"9453_CR22","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.14218\/JCTH.2022.00130S","volume":"11","author":"KS Cheung","year":"2023","unstructured":"Cheung KS, Mok CH, Lam LK et al. Carvedilol Versus Other Nonselective Beta Blockers for Variceal Bleeding Prophylaxis and Death: A Network Meta-analysis. J Clin Transl Hepatol. 2023;11:1143\u20131149. https:\/\/doi.org\/10.14218\/JCTH.2022.00130S.","journal-title":"J Clin Transl Hepatol."},{"key":"9453_CR23","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1002\/lt.24794","volume":"23","author":"C Moctezuma-Velazquez","year":"2017","unstructured":"Moctezuma-Velazquez C, Kalainy S, Abraldes JG. Beta-blockers in patients with advanced liver disease: Has the dust settled? Liver Transpl. 2017;23:1058\u20131069. https:\/\/doi.org\/10.1002\/lt.24794.","journal-title":"Liver Transpl."},{"key":"9453_CR24","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1111\/apt.14576","volume":"47","author":"R Schwarzer","year":"2018","unstructured":"Schwarzer R, Kivaranovic D, Paternostro R et al. Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response study. Alimentary Pharmacology & Therapeutics. 2018;47:1162\u20131169. https:\/\/doi.org\/10.1111\/apt.14576.","journal-title":"Alimentary Pharmacology & Therapeutics."},{"key":"9453_CR25","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1053\/j.gastro.2013.10.018","volume":"146","author":"E Reverter","year":"2014","unstructured":"Reverter E, Tandon P, Augustin S et al. A MELD-based model to determine risk of mortality among patients with acute variceal bleeding. Gastroenterology. 2014;146:412-419.e3. https:\/\/doi.org\/10.1053\/j.gastro.2013.10.018.","journal-title":"Gastroenterology."},{"key":"9453_CR26","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/hep.23775","volume":"52","author":"T Serst\u00e9","year":"2010","unstructured":"Serst\u00e9 T, Melot C, Francoz C. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatol Baltim Md. 2010;52:1017\u20131022. https:\/\/doi.org\/10.1002\/hep.23775.","journal-title":"Hepatol Baltim Md."},{"key":"9453_CR27","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.jhep.2011.01.034","volume":"55","author":"T Serst\u00e9","year":"2011","unstructured":"Serst\u00e9 T, Francoz C, Durand F. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. J Hepatol. 2011;55:794\u2013799. https:\/\/doi.org\/10.1016\/j.jhep.2011.01.034.","journal-title":"J Hepatol."},{"key":"9453_CR28","doi-asserted-by":"publisher","unstructured":"EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406\u2013460. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.024","DOI":"10.1016\/j.jhep.2018.03.024"},{"key":"9453_CR29","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.cgh.2019.05.050","volume":"18","author":"L Turco","year":"2020","unstructured":"Turco L, Villanueva C, La Mura V et al. Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis. Clin Gastroenterol Hepatol. 2020;18:313-327.e6. https:\/\/doi.org\/10.1016\/j.cgh.2019.05.050.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"9453_CR30","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jhep.2020.03.048","volume":"73","author":"E Alvarado-Tapias","year":"2020","unstructured":"Alvarado-Tapias E, Ardevol A, Garcia-Guix M et al. Short-term hemodynamic effects of \u03b2-blockers influence survival of patients with decompensated cirrhosis. J Hepatol. 2020;73:829\u2013841. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.048.","journal-title":"J Hepatol."},{"key":"9453_CR31","doi-asserted-by":"publisher","first-page":"287","DOI":"10.20524\/aog.2019.0368","volume":"32","author":"K Malandris","year":"2019","unstructured":"Malandris K, Paschos P, Katsoula A et al. Carvedilol for prevention of variceal bleeding: a systematic review and meta-analysis. Ann Gastroenterol. 2019;32:287\u2013297. https:\/\/doi.org\/10.20524\/aog.2019.0368.","journal-title":"Ann Gastroenterol."},{"key":"9453_CR32","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1097\/MCG.0000000000001431","volume":"55","author":"GN Kalambokis","year":"2021","unstructured":"Kalambokis GN, Christaki M, Tsiakas I. Conversion of Propranolol to Carvedilol Improves Renal Perfusion and Outcome in Patients With Cirrhosis and Ascites. J Clin Gastroenterol. 2021;55:721\u2013729. https:\/\/doi.org\/10.1097\/MCG.0000000000001431.","journal-title":"J Clin Gastroenterol."},{"key":"9453_CR33","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jceh.2020.08.009","volume":"11","author":"S Sharma","year":"2021","unstructured":"Sharma S, Agarwal S, Gunjan D. Long-term Outcomes with Carvedilol versus Propranolol in Patients with Index Variceal Bleed: 6-year Follow-up Study. J Clin Exp Hepatol. 2021;11:343\u2013353. https:\/\/doi.org\/10.1016\/j.jceh.2020.08.009.","journal-title":"J Clin Exp Hepatol."},{"key":"9453_CR34","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jhep.2017.02.005","volume":"67","author":"R Sinha","year":"2017","unstructured":"Sinha R, Lockman KA, Mallawaarachchi N, Robertson M, Plevris JN, Hayes PC. Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites. J Hepatol. 2017;67:40\u201346. https:\/\/doi.org\/10.1016\/j.jhep.2017.02.005.","journal-title":"J Hepatol."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09453-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-025-09453-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09453-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T08:42:25Z","timestamp":1777970545000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-025-09453-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,18]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["9453"],"URL":"https:\/\/doi.org\/10.1007\/s10620-025-09453-6","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,18]]},"assertion":[{"value":"1 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}